Close menu




November 9th, 2021 | 12:02 CET

SAP, Qualtrics, TeamViewer, Osino Resources - Watch out, these stocks are way too cheap!

  • Investments
Photo credits: pixabay.com

Sometimes things do not work out as expected on the stock market. At the beginning of October, the DAX started to sell off, the 200-day line was even clearly undercut twice at 14,850 points, and many crash prophets became quite loud again. However, as is so often the case, they were again not proven right, as the market exited trading last Friday at a new all-time high of 16,033 points. Who would have thought it - a whopping 1200 point reversal, the proclaimed crash was canceled again without a sound. We look at exciting stocks in a very volatile environment.

time to read: 4 minutes | Author: André Will-Laudien
ISIN: OSINO RESOURCES CORP. ON | CA68828L1004 , SAP SE O.N. | DE0007164600 , TEAMVIEWER AG INH O.N. | DE000A2YN900

Table of contents:


    SAP - Subsidiary Qualtrics performs exceptionally well

    Qualtrics is the American subsidiary of the German software company SAP and a specialist in enterprise feedback management. According to the Company, Qualtrics software is used by more than 11,000 corporate customers worldwide. In November 2018, Qualtrics was acquired as a bargain by SAP for about USD 8 billion. From January to September 2020, Qualtrics' 3,300 employees were already generating revenue of USD 550 million.

    SAP then listed its subsidiary in the US at the end of January 2021. The Company raised the price range for its shares from USD 24 to USD 30 given the high demand, which put the proceeds from the IPO at around USD 1.5 billion. The allotment then also took place at USD 30. Today, the stock is trading at USD 43.5 and has a market capitalization of a hefty USD 22.5 billion. It is already one of the few successful US IPOs in German history.

    Following this success, the first capital increase at Qualtrics is now taking place ten months later. The SAP subsidiary aims to raise up to USD 1 billion by issuing new shares. The offer price of USD 42 is based on the current share price. At the moment, you probably have to ride the wave on the NASDAQ because German technology companies have rarely achieved higher issue proceeds in the USA. This is good for the parent company SAP as well as for the subsidiary.

    With the positive newsflow, SAP recently left its downward trend and is preparing to climb back up the old upward trend. It is not an easy undertaking, as there is still massive resistance at EUR 128 on the upside. Should this fall, the target price is EUR 143.50. However, with the current operational progress, especially in the cloud business, the move should ultimately succeed.

    Osino Resources - Capital increase successfully placed

    Osino Resources may be receiving a lot of encouragement from its investors. Its portfolio of exclusive exploration licenses is located within the prospective Damara mineral belt in Namibia, mainly near the producing Navachab and Otjikoto gold mines on a total area of about 6,700 sq km.

    In the current drill program, Osino Resources hopes to significantly expand on the initial estimate from the second quarter of this year of 430,000 ounces at 1.00-1.08 g/t gold (indicated and inferred, respectively). The necessary capital was currently raised through a capital increase. Osino placed 9.545 million shares at CAD 1.10, including a half warrant at CAD 1.35 for 22 months. The use of the capital is primarily for exploration purposes at the Twin Hills Gold Project. It is also intended for assays, technical studies, acquisition of surface rights and general corporate purposes. We believe the current financing should cover all obligations until the end of 2022.

    Overall, analysts at Sprott Equity Research are very optimistic and see further high-grade discoveries in the upcoming 75,000m drill program. From the current level at around CAD 1.26, the share is expected to move up 100% with a buy recommendation. The Osino share has already gained 20% in only five trading days and is poised to reach the high of about CAD 1.60 again.

    TeamViewer - Bad figures and what is next?

    A black shadow has been hanging over the TeamViewer share for several months now. In the third quarter, investors were once again disappointed. TeamViewer was able to gain around 5,000 new customers, but in the previous quarters, there were about 20,000 additions in each case. The current customer retention rate is 99%, which is somewhat encouraging. In the second quarter, this rate was only 88%. It seems business is returning to normal after the pandemic hype. Nevertheless, the Company must now show that it can perform well in a normal environment.

    Management currently provides the following guidance: For fiscal 2021, the company is forecasting an adjusted EBITDA margin of only 44% to 46% instead of the previous 49% to 51%. At EUR 495 to 505 million, sales are also expected to be around 7% lower than the EUR 525 to 540 million forecast. This is not a great forecast, but it is not a disaster for the heavily discounted share price.

    The analysts have adjusted their ratings accordingly and now expect an average share price of EUR 19.5 on a 12-month horizon. However, the analysts at DZ Bank only confirm a hold recommendation for TeamViewer with a low price target of EUR 16.20. The analysts continue to expect earnings per share of EUR 0.67 in the current year and EUR 0.81 in 2022. Therefore, the P/E ratio for 2022 is just under 18, which is not too expensive for a growth stock.

    Now the Management Board must win back the lost trust of its investors as quickly as possible. The first opportunity will be at the upcoming Capital Markets Day tomorrow, November 10. Wait for the event with confidence and observe what comes to light here; jump on the bandwagon if necessary.


    SAP and TeamViewer are currently developing quite differently. With its branding, TeamViewer has become very dependent on SAP. Because of the lower valuation, a takeover could be imminent. SAP is well on the way to regaining its former strength. At Osino Resources, all lights are green following the capital increase.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read